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Cisplatin-induced changes in sodium, chloride, and urea trans-
port by the frog skin. Cisplatin is a platinum-containing antitumor
agent whose usefulness is limited by nephrotoxicity. We exam-
ined the effects of cisplatin on a representative, transporting epi-
thelium—the frog skin. Cisplatin (l0- M) from the mucosal sur-
face increased the active transport of sodium by 35 to 40%, as
monitored by short-circuit current. The cisplatin-induced in-
crease in short-circuit current was inhibited by amioride and
was additive to the effects of vasopressin (20 mU/ml of serosal
solution). Cisplatin from the mucosal surface also decreased
transepithelial electrical resistance by about 35% and increased
the permeability to sodium, chloride, and urea. None of these
effects of cisplatin occurred with platinum sulfate, platinum chlo-
ride, or the trans-isomer of cisplatin. Accordingly, we conclude
that cisplatin increases the permeability of the mucosal surface
of the frog skin to sodium, chloride, and urea and that these
changes are related to the cis-configuration of the drug rather
than simply its heavy metal moiety.
Modification des transports de sodium, de chlore, et d'urée par
Ia peau de grenouille sous l'infiuence du cisplatine. Le cisplatine
est un agent anti-tumoral qui contient du platine et dont
l'utilisation est limitée par Ia néphrotoxicité. Nous avons étudié
les effets du cisplatine sur la peau de grenouille qui est repré-
sentative d'un épithélium de transport. Le cisplatine a la concen-
tration de l0 M a la face muqueuse augmente le transport actif
de sodium, évalué par le courant de court-circuit, de 35 a 40%.
L'augmentation du courant de court circuit induite par le cispla-
tine est inhibée par l'amiloride et est additive aux effets de 20
mU de vasopressine dans la solution séreuse. Le cisplatine a Ia
face muqueuse diminue Ia résistance électrique transépithéliale
de 35% et augmente Ia perméabilité au sodium, au chlore et a
l'urée. Aucun des effets du cisplatine n'a été observe avec le
sulfate de platine, le chlorure de platine ou l'isomére trans du
cisplatine. Nous en concluons que le cisplatine a Ia face mu-
queuse de Ia peau de grenouille augmente la perméabilité au so-
dium, au chiore et a l'urée et que ces modifications sont en rap-
port avec la configuration cis de la drogue plus qu'avec Ia pré-
sence de metal lourd.
Cisplatin (cis-diamminedichloroplatinum) is a
heavy-metal-containing antitumor agent that is ef-
fective in the treatment of various malignancies [1-
3] but whose usefulness is limited by nephrotoxicity
[4-6]. Although the mechanisms of this nephrotox-
icity are largely unexplored, it has been presumed
that nephrotoxicity results from the direct effects of
the heavy metal moiety, platinum, and that the kid-
neys are affected most prominently because of their
role in the excretion of the drug [4—8]. There are,
however, problems with this construction. The liver
achieves tissue concentrations of platinum com-
parable to those that occur in the kidney and yet
hepatotoxicity does not occur with cispiatin [5, 7, 9—
10]. The striking absence of hepatotoxicity coupled
with prominent renal toxicity raises questions about
the special vulnerability of transporting epithelia to
the toxic effects of cisplatin and about the toxicity
of platinum itself.
The purpose of the present studies is twofold;
first, to examine the effects of cisplatin on the frog
skin as a model of transporting epithelia, and sec-
ond, to compare the effects of cisplatin to those of
other platinum compounds. The results indicate
that cisplatin has rapid and direct effects on the frog
skin that we relate to increases in the solute per-
meabilities of both the transcellular and paracellular
transport pathways. These effects do not occur with
either the trans-isomer of cisplatin or with platinum
chloride or platinum sulfate. The effects of cisplatin
on the frog skin are therefore dependent on some
structural configuration of the drug other than sim-
ply the presence of the heavy-metal platinum
moiety.
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Ventral skins were dissected from fasted Rana pi-
piens berliendieri and were mounted as flat sheets
(3.14 cm2) between two plastic (Lucite) chambers
equipped with 10-mi solution reservoirs. The cham-
Cisplatin's effect on frog skin 9
bers were stirred and oxygenated with air. The elec-
trical potential difference across the skin (with ref-
erence to the outside surface of the frog skin) was
measured with calomel electrodes, and current was
passed through the skin via silver-silver chloride
electrodes. Electrodes were connected to the cham-
bers with agar bridges of the same fluid composition
as the solutions in the chambers. An automatic volt-
age clamp was used to pass sufficient current (short-
circuit current) to maintain the transepithelial elec-
trical potential at zero. This short-circuit current
(I; A/cm2) was used to monitor active sodium
transport. Transepithelial electrical resistance (Rt;
ohm cm2) was calculated from I and the open-
circuit transepithelial electrical potential difference.
Unidirectional fluxes of chloride and urea and of
sodium and urea were measured from the serosal
(inside or blood) side to the mucosal (outside or
pond) side. All experiments were done under short-
circuit conditions with brief interruptions to mea-
sure the open-circuit potential. Fluxes were calcu-
lated from the specific activities of the isotopes
added to the inside chamber (36C1, 22Na, and 14C-urea)
and their rates of accumulation in the outside cham-
ber. Two or three 15- to 20-mm flux periods were
measured during each experimental condition. Iso-
topes were measured by liquid scintillation counting
in Aquasol (New England Nuclear, Boston, Massa-
chusetts) plus 0.6% water by volume.
The composition of the standard frog Ringer solu-
tion was 110 m sodium chloride, 2.5 m potas-
sium bicarbonate, 1.0 ifiM calcium chloride, and 1.0
m urea. All solutions were maintained at a tem-
perature of 22° C and a pH of 7.4. As noted, some
studies were done with sulfate-Ringer: 55 mM so-
dium sulfate, 2.0 m potassium bicarbonate, 1.0
m calcium chloride, and 1.0 mrvi urea. Cisplatin
(Platinol; Bristol-Myers Co., Syracuse, New
York) was dissolved in Ringer solution and was
added directly to the appropriate chamber. As sup-
plied by the manufacturer, cisplatin contains 100 mg
of mannitol per vial. This led to final concentrations
of mannitol in the chamber of up to 4 mg/ml, but
separate studies indicated that mannitol at this con-
centration had no effect on the frog skin. Regard-
less, mannitol was added to the chamber in those
studies that involved the trans-isomer or platinum
salts. Other agents used in the present studies in-
clude platinum sulfate and platinum chloride (ICN
Pharmaceuticals, Inc., Plainview, New York),
trans-diamminedichloroplatinum (Vega, Tucson,
Arizona), vasopressin (Parke, Davis, and Co., De-
troit, Michigan), and amiloride (Merck, Sharp, and
Dohme Research Laboratories, West Point, Penn-
sylvania).
Each skin was equilibrated under short-circuit
conditions in chloride or sulfate-Ringer solution for
at least 1 hour prior to the measurement of control
values. For those studies that involved measure-
ments of radioisotopic fluxes, only skins with trans-
epithelial electrical resistance greater than 1,000
ohm cm2 were used. Statistical probabilities were
calculated by Student's paired t test. Data are ex-
pressed as the mean SEM for the number of skins
in each group.
Results
Effects of cisplatin from the mucosal side. Cispla-
tin added to the mucosal side increased the short-
circuit current and decreased the transepithelial
electrical resistance. These effects occurred at cis-
platin concentrations of l0 to l0 M, but were
more rapid and consistent at 10 M. Concentrations
of 10-6 and 10 M had no effect. Accordingly, all
reported data were obtained at l0 M cisplatin.
As shown in Fig. 1, cisplatin (10-s M) from the
mucosal side increased the short-circuit current rap-
idly to values that averaged 35 to 40% above control
values. This increase in short-circuit current was sus-
tained in all studies for at least 20 mm but with in-
creasing variability beyond 30 mm. This variability
is accounted for by the tendency in some skins for
Is,, to increase gradually over 60 mm (4/20 studies)
or, in other skins, to decrease below control values
after the initial rise (3/20 studies). Overall, for the 20
studies in Fig. 1, cisplatin increased from 32.8
3.4 to 46.2 4.1 AIcm2 at 20 mm (P <0.001). The
effect was reversible if the drug was removed within
about 20 mm.
Cisplatin added to the mucosal side also de-
creased transepithelial electrical resistance from
control values of 1568 156 to 1056 31 ohm cm2
at 20 mm or 67.5% of control values (P < 0.001). As
shown in Fig. 2, this effect was stable for 60 to 80
mm after the addition of cisplatin.
The cisplatin-induced increase in the short-circuit
current was inhibited by amioride. Each of six
skins was exposed first to rapid increases in amilo-
ride concentration in the mucosal chamber. Amilo-
ride was then removed, and 10 M cisplatin was
added from the mucosal side. Mter 10 mm, a sec-
ond dose-response to amiloride was obtained. Fig-
ure 3 shows the results of these six paired studies of
the effects of amiloride on I in the absence and in
the presence of cisplatin. Data are expressed as the
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Fig. 1. Effects of cisplatin on short-circuit current by the frog
skin (N = 20). Cisplatin was added to the mucosal chamber to a
final concentration of 10 M.
percent of control that averaged 43.6 6.3 pAJcm2
in the absence of cisplatin and 63.4 11.4 jzA/cm2
in the presence of cisplatin. A 50% inhibition of
occurred at 5 X l0 M amiloride in both the ab-
sence and presence of cisplatin, and there was no
change in the ability of amiloride to inhibit com-
pletely.
The effects on 'Sc of cisplatin from the mucosal
side were additive to the effects of ADH added to
the serosal surface. As shown in Fig. 4, regardless
of whether cisplatin or ADH was added first, the
combined presence of both agents resulted in signif-
icant increases in L over the values observed in the
presence of only one agent.
The decreases in transepithelial electrical resis-
tance caused by cisplatin were examined further by
the measurements of sodium, chloride, and urea
backfluxes from serosal to mucosal solutions. Sev-
en studies examined the simultaneous changes in
chloride and urea fluxes, and eight other studies ex-
amined the simultaneous changes in sodium and
urea transport. We considered urea fluxes to repre-
sent solute transport via the shunt pathway, as has
been shown for both high- and low-resistance frog
Time, rn/n
Fig. 2. Effect of cisplatin on transepithelial electrical resistance(N = 20). Cisplatin was added to the mucosal chamber to a final
concentration of lO M.
skins [11, 12]. Cisplatin (l0— M) from the mucosal
side increased the backflux of sodium from 65.8
17.0 to 225.5 37.8 nEq/cm2 hr (P < 0.001), of
chloride from 110.0 18.5 to 364.9 97.2 nEq/cm2
hr (P <0.05), and of urea from 0.60 0.09 to 1.92
0.44 nmoles/cm2 hr (P < 0.02). Moreover, as
shown in Figs. S and 6, the increases in chloride and
in sodium fluxes were proportional in each study
to the increases in urea fluxes measured simulta-
neously.
Effects ofcisplatin from the serosal side. If added
to only the serosal side, cisplatin decreased rather
than increased the short-circuit current. Again, this
effect occurred at concentrations that ranged be-
tween l0- and l0 M, but was most consistent at
10 M. For ten skins, cisplatin (10 M) in the sero-
sal chamber decreased L from 57.2 8.5 to 23.1
4.5 pA/cm2 (P <0.01) without changes in sodium
backflux (four studies). Transepithelial electrical re-
sistance increased from 1114 270 to 2288 470
ohm cm2 (P < 0.005). These effects were revers-
ible if cisplatin was removed within 15 to 20 mm.
The addition of antidiuretic hormone (ADH) at 20
mU/mi of serosal fluid stimulated 'Sc even in the
presence of cisplatin on the same side (22.67 5.5
vs 36.6 4.1 Aicm2;P <0.02;N = 6). Thus, cis-
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Fig. 3. Dose-response curves to amiloride measured in the ab-
sence or presence of cisplatin 1O M in the outside chamber.
Data are expressed as percent of control that averaged 43.6 6.3
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Fig. 5. Effects of cisplatin on the backflux of chloride and urea.
Cisplatin was added to the mucosal side to a final concentration
of l0' M. Each line connects the control and experimental val-
ues for a single frog skin after at least 10 mm's exposure to cis-
platin. The equation expresses the linear relationship among the
control and experimental points.
platin from the serosal side inhibits 'Sc but the inhi-
bition is incomplete at l0 M.
Effects of other platinum compounds. Trans-
diamminedichioroplatinum, platinum chloride, and
platinum sulfate in either the mucosal or serosal
chamber had no effect on R, or transepithelial
electrical potential difference. Platinum chloride
and platinum sulfate were added to either the mu-
cosal or serosal sides to final concentrations of l0
M. Separate studies were performed for each agent
with either sulfate-Ringer or chloride-Ringer so-
lutions, and no effects were noted under either con-
dition. Because of its lower solubility, trans-diam-
minedichloroplatinum was added to the chambers
to final concentrations of only 5 X 10 M without
effect. For comparison, in three separate skins, 5 x
10 M cisplatin from the mucosal side increased Ia,
from 70.2 15.8 to 78.3 17.0 tAicm2 (P <0.05).
There was a tendency for trans-diamminedichloro-
platinum from the mucosal side to increase the
transepithelial electrical resistance (1380 197 vs.
1642 269 ohm cm2) but the change was not sta-
tistically signfficant.
I
0 Control CP CP+ADH Control ADH ADH+CP
Fig. 4. Interactions between cisplatin and ADH. ADH was added
to the serosal chamber to a final concentration of 20 mU/mi. Con-
trol values were measured in the presence of frog Ringer solution
only. Cisplatin (CP) was added to the mucosal side either before
or after ADH. Each bar represents the mean SEM for five to six
skins. Asterisks (5) denote significant increases relative to the
preceding bar.
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Discussion
These studies demonstrate that cisplatin has rap-
id and direct effects on solute transport by the frog
skin. When added to serosal surface, cisplatin inhib-
ited active sodium transport, as monitored by short-
circuit current. If added to the mucosal surface, cis-
platin increased active sodium transport and de-
creased transepithelial electrical resistance. The ef-
fects of cisplatin from the mucosal side were ac-
companied by increases in the permeability of the
frog skin to sodium, chloride, and urea. On the oth-
er hand, none of these effects occurred with either
the trans-isomer of cisplatin or with platinum chlo-
ride or platinum sulfate. We interpret these data to
indicate that cisplatin from the mucosal side in-
creases transport through both the active, trans-
cellular pathway as well as through the passive,
shunt pathway. Moreover, these effects of cisplatin
are not related to its platinum moiety alone, but to
some other feature of its structure.
The present models of sodium transport across
the frog skin [13, 14] include an active transport
pathway that is monitored by short-circuit current,
and a parallel shunt pathway that under normal or
control conditions has very low sodium con-
ductance but contributes importantly to trans-
epithelial electrical resistance. The parallel shunt
pathway may [11] or may not be entirely para-
cellular [15]. Active transport of sodium is trans-
cellular and consists of a rate-limiting sodium entry
step located at the mucosal barrier and metabolic-
ally dependent sodium extrusion via sodium-potas-
sium-activated ATPase along the serosal surface.
According to the above model, increases in 'Scor
active sodium transport such as those observed
with cisplatin from the mucosal side could result
from increased permeability to sodium at the entry
site or to direct stimulation of the pump. The latter
possibility seems less likely in view of the observa-
tion that cisplatin from the serosal surface inhibits
and increases R. Accordingly, we favor the pos-
sibility that cisplatin from the mucosal side in-
creased I by increasing the permeability of the so-
dium entry barrier, but we acknowledge that defini-
tion of the exact mechanism will require more direct
information such as that obtained from recordings
of intracellular potentials [16—18].
The data with regard to amioride, the specific in-
hibitor of sodium entry [19], indicate two features of
cisplatin' s effects from the mucosal side. First, be-
cause the dose-response curve for amioride was
not affected by cisplatin (Fig. 3), we conclude that
cisplatin has no effect on the amiloride-sensitive
site. Stated in another way, cisplatin acts at a site
different from that of amiloride, which is considered
to act directly at, or close to [20, 21], the entry of
the sodium channel. Second, because amiloride in-
hibits completely the cisplatin-induced increase in
there is no support for the possibility that cispla-
tin may have caused new, less specific entry path-
ways. That is, cisplatin increased sodium con-
ductance through the amiloride-sensitive pathway.
In this regard, it is useful to compare the effects
of cisplatin to those of other agents that enhance
active sodium transport by the frog skin. ADH, for
example, also increases but the effects of cis-
platin on I, are additive to the effects of maximal
concentrations [22] of ADH (Fig. 4). Accordingly,
cisplatin and ADH apparently act at different sites
or via different mechanisms. Amphotencin B also in-
creases and decreases R [23] in a pattern similar
to cisplatin, but the effects of amphotericin B, at
least in the toad bladder, are not inhibited by amilo-
ride [24, 25]. This suggests that amphotericin B may
form new entry sites for sodium in parallel with the
amiloride-sensitive site. On the other hand, a series
of other agents, such as benzoylimidazole-guanidine
(BIG) and para-chloromercuribenzoate (PCMB) or
its sulfonate (PCMBS), increase apparently by
1.0 2.0 3.0 4.0 5.0
Backflux of urea, nmo/es/cm2 . hr
Fig. 6. Effects of cisplatin on the backflux of sodium and urea.
The conditions are the same as they are for Fig. 5.
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prolonging the open-phase of the sodium channel
[14, 26, 27]. The effects of these agents resemble the
effects of cisplatin on 'Sc and, as with cisplatin, are
blocked by amiloride. That is, the sites of BIG,
PCMB, and cisplatin act as if in series with the
amiloride-sensitive site. It is not certain, of course,
whether cisplatin acts at the same site or by the
same mechanism as PCMB. Nevertheless, it is rea-
sonable to hypothesize that all these agents increase
I by increasing sodium entry at the rate-limiting
outer surface.
It should be emphasized that the possible effects
of cisplatin on sodium entry and short-circuit cur-
rent may not account fully for the effects of cisplatin
on transepithelial electrical resistance, which is de-
termined by the tight junctions as well as the outer
membrane [13, 15-18]. Differentiation among the
three major resistances —outer membrane, inner
membrane, and shunt—requires measurements of
changes in intracellular electrical potentials. In the
absence of such studies, we looked for evidence of
increased conductance through the shunt pathway.
As shown in Figs. 5 and 6, the decrease in R caused
by cisplatin on the outside was associated with the
increased permeability to sodium, chloride, and
urea. Moreover, these increases in the permeation
of sodium and of chloride were proportional in each
instance to the increases in urea fluxes measured
simultaneously. These observations may be inter-
preted in the context of studies by Ussing and
Windhager [28] and by Mandel and Curran [11, 12]
who noted that exposure of frog skins to external
hypertonic urea decreased R without affecting Ic.
Presumably, therefore, hypertonic urea decreased
the resistance of an extracellular pathway not in-
volved directly in the active transport of sodium.
Under these conditions, the backfluxes of sodium
and of chloride increased in proportion to the in-
creases in urea fluxes and to the relative con-
ductances of sodium and chloride in free solution.
Linearity between sodium and urea fluxes was
maintained under a variety of conditions such as
ADH, theophylline [12], and depolarizing external
potentials [11] that increased sodium and urea back-
fluxes. These data are interpreted to indicate that
these conditions increase permeation through an
extracellular pathway and that this pathway is
equivalent to a "free-solution shunt" with regard to
sodium, chloride, and urea. Similarly, in the present
studies, for each skin tested (Figs. 5 and 6), the cis-
platin-induced increases in sodium or chloride
fluxes were highly correlated with the increases in
urea fluxes. To the extent that urea in the presence
of cisplatin still represents an adequate indicator of
the extracellular transport pathway across the frog
skin, these data indicate that cisplatin increases per-
meation through the shunt pathway. At a minimum,
the proportional increases in sodium, chloride, and
urea fluxes indicate that cisplatin increases move-
ment through some pathway shared by these three
solutes.
On the basis of these data, we conclude that cis-
platin has three major effects on membrane func-
tions of the frog skin. First, cisplatin from the mu-
cosal surface increases active sodium transport by
increasing the permeability of the outer cellular
membrane to sodium. Second, cisplatin at the same
time decreases transepithelial electrical resistance
in part by its effects on the outer cellular membrane
but also by increases in the permeability or con-
ductance of the shunt pathway. Third, cisplatin
from the serosal surface inhibits incompletely the
active transport of sodium by mechanisms that may
involve inhibition of ATPase activity, as suggested
by Guarino et al [29], or by direct interference with
ionic conductances as has been demonstrated to oc-
cur with barium [30].
None of these effects of cisplatin occurred with
the other platinum compounds that were tested. In
particular, the trans-isomer of cisplatin had no ef-
fects. Besides serving as controls for the studies with
cisplatin, these data indicate that the effects of cis-
platin on the frog skin cannot be attributed to plati-
num alone but to the cis-configuration of the entire
complex. These data are consistent with observa-
tions in various experimental systems demonstrat-
ing that the trans-isomers of platinum complexes do
not have either antitumor or nephrotoxic activity
[I].
The relationship between the present studies and
the effect of cisplatin in man is uncertain. The
chemical forms of cisplatin in vivo and their con-
centration in the kidney during excretion are largely
unknown. The present studies, however, indicate
that cisplatin has direct effects on membrane per-
meabilities of the frog skin, an epithelium that
shares many characteristics of the mammalian col-
lecting ducts. Moreover, the cisplatin-induced
changes are not dependent on the platinum moiety
alone, but on some function of associated groups
and their configuration.
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